ESCRS Showcase

Article

Some of the products that company's will shoiwcase at this year's ESCRS.

Corneal protection

CROMA will focus on the protection of the corneal surface during and after surgery. Hydration and protection of the cornea during surgical procedures are achieved with CORNEA_PROTECT® sterile single-dose units. HYLO-CARE® is a preservative-free therapeutic combination of sodium hyaluronate and dexpanthenol for the hydration and support of an enhanced healing process of the epithelium.

CROMA is performing research in the field of biomolecules and has developed the THIOMERS, a unique technology combining macromolecules, such as hyaluronic acid, with human amino acid (cysteine) for novel ophthalmic applications. In the field of dry eye, the THIOMER-based biopolymers will be able to covalently bind to the corneal surface and form a protective layer for more than 22 hours. This technology will be presented during CROMA´s satellite symposium.

What's new in retina

SLT in review of a decade

The introduction of Selective Laser Trabeculoplasty (SLT) represented the first fundamental change in laser treatment for open-angle glaucoma in many years. Following a decade of scientific and clinical experience, Lumenis has gathered a team of leading experts to discuss and debate the role of this unique technology. The faculty will address topics such as the current role of SLT in glaucoma management, how and when to apply the technology, patient selection and success predictors, long-term efficacy, repeatability, the most up-to-date clinical treatment protocol to ensure successful outcomes, and more.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.